Indoco Remedies Management Meet Update: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We recently had an interaction with the management of Indoco Remedies Ltd. to discuss the outlook for various business segments and future plans. Given below are certain key takeaways from our discussion:
Baddi 3 unit is currently operating at 70% utilisation. At peak, the company aims to do Rs 4,500 million in annual revenue from this unit. This would be aided by a shift in product mix and a minor de-bottlenecking exercise.
The company expects to move manufacturing for four high-value products from Goa to Baddi Unit 3.
The Rs 2500 million revenue target for the U.S. market in FY22 is largely driven by the ramp-up in the existing portfolio.
The key triggers in the U.S. market during the year would be the relaunch of ophthalmic products, which is expected in mid-FY22.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.